Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTRACTION-5: Adjuvant Nivolumab in Gastric Cancer
NCT03006705Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2017
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of nivolumab in gastric cancer (GC), sponsored by Ono Pharmaceutical. Started Jan 2017; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03006705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03006705.